The role of science in addressing the opioid crisis

New England Journal of Medicine

Volumn 377, Issue 4, 2017, Pages 391-394

  Volkow, Nora D ^a,b   Collins, Francis S ^b  

^a NATIONAL INSTITUTE ON DRUG ABUSE   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BUPRENORPHINE; CARFENTANIL; DIAMORPHINE; DOPAMINE 3 RECEPTOR BLOCKING AGENT; FENTANYL; LOFEXIDINE; LORCASERIN; METHADONE; NALOXONE; NALTREXONE; OLICERIDINE; OPIATE; SEROTONIN 1A AGONIST; NARCOTIC ANALGESIC AGENT;

ARTICLE; CHRONIC PAIN; DRUG EFFICACY; DRUG MISUSE; DRUG OVERDOSE; DRUG SAFETY; DRUG SEEKING BEHAVIOR; DRUG TARGETING; FATALITY; HUMAN; MORPHINE ADDICTION; NATIONAL HEALTH ORGANIZATION; NERVE STIMULATION; NONHUMAN; OPIATE ADDICTION; PERSONALIZED MEDICINE; PRIORITY JOURNAL; PUBLIC-PRIVATE PARTNERSHIP; REPETITIVE TRANSCRANIAL MAGNETIC STIMULATION; RESPIRATION DEPRESSION; ANALGESIA; OPIOID-RELATED DISORDERS; PROCEDURES; SCIENCE;

ANALGESICS, OPIOID; DRUG OVERDOSE; HUMANS; OPIOID-RELATED DISORDERS; PAIN MANAGEMENT; PUBLIC-PRIVATE SECTOR PARTNERSHIPS; SCIENCE;

EID: 85026322064     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMsr1706626     Document Type: Article

References (10)

1. Rudd RA, Seth P, David F, Scholl L. Increases in drug and opioid-involved overdose deaths — United States, 2010–2015. MMWR Morb Mortal Wkly Rep 2016;65:1445-52.
2. Tomassoni AJ, Hawk KF, Jubanyik K, et al. Multiple fentanyl overdoses — New Haven, Connecticut, June 23, 2016. MMWR Morb Mortal Wkly Rep 2017;66:107-11.
3. Volkow ND, Frieden TR, Hyde PS, Cha SS. Medication-assisted therapies — tackling the opioid-overdose epidemic. N Engl J Med 2014;370:2063-6.
4. Bremer PT, Kimishima A, Schlosburg JE, Zhou B, Collins KC, Janda KD. Combatting synthetic designer opioids: a conjugate vaccine ablates lethal doses of fentanyl class drugs. Angew Chem Int Ed Engl 2016;55:3772-5.
5. Huang W, Manglik A, Venkatakrishnan AJ, et al. Structural insights into μ-opioid receptor activation. Nature 2015;524:315-21.
6. Eon V, Giuvelis D, Ananthan S, Bilsky E. Efficacy of dopamine D3 receptor antagonist SR 21502 in reducing opioid tolerance and dependence. FASEB J 2015;29:Suppl 6:415. abstract.
7. Mulcahy JV. Development of selective inhibitors of NAV1.7 as therapeutics for pain. Bethesda, MD: National Institutes of Health, 2016 (https://projectreporter.nih.gov/project_info_description.cfm?aid=9202883&icde=34005320&ddparam=&ddvalue=&ddsu b=&cr=2&csb=default&cs=ASC&pball=%3E).
8. Dodick DW, Goadsby PJ, Silberstein SD, et al.Safety and efficacy of ALD403, an antibody to calcitonin gene-related peptide, for the prevention of frequent episodic migraine: a randomised, double-blind, placebo-controlled, exploratory phase 2 trial. Lancet Neurol 2014;13:1100-7.
9. Guedon JM, Wu S, Zheng X, et al. Current gene therapy using viral vectors for chronic pain. Mol Pain 2015;11:27.
10. Kwilasz AJ, Grace PM, Serbedzija P, Maier SF, Watkins LR. The therapeutic potential of interleukin-10 in neuroimmune diseases. Neuropharmacology 2015;96:55-69.